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Disruption of mesoderm formation 
during cardiac differentiation due 
to developmental exposure to 
13-cis-retinoic acid
Qing Liu1, Kevin Van Bortle1, Yue Zhang1,2, Ming-Tao Zhao3, Joe Z. Zhang3, 
Benjamin S. Geller1, Joshua J. Gruber1,4, Chao Jiang1, Joseph C. Wu3 & Michael P. Snyder1
13-cis-retinoic acid (isotretinoin, INN) is an oral pharmaceutical drug used for the treatment of skin 
acne, and is also a known teratogen. In this study, the molecular mechanisms underlying INN-induced 
developmental toxicity during early cardiac differentiation were investigated using both human induced 
pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs). Pre-exposure of hiPSCs 
and hESCs to a sublethal concentration of INN did not influence cell proliferation and pluripotency. 
However, mesodermal differentiation was disrupted when INN was included in the medium during 
differentiation. Transcriptomic profiling by RNA-seq revealed that INN exposure leads to aberrant 
expression of genes involved in several signaling pathways that control early mesoderm differentiation, 
such as TGF-beta signaling. In addition, genome-wide chromatin accessibility profiling by ATAC-seq 
suggested that INN-exposure leads to enhanced DNA-binding of specific transcription factors (TFs), 
including HNF1B, SOX10 and NFIC, often in close spatial proximity to genes that are dysregulated 
in response to INN treatment. Altogether, these results identify potential molecular mechanisms 
underlying INN-induced perturbation during mesodermal differentiation in the context of cardiac 
development. This study further highlights the utility of human stem cells as an alternative system for 
investigating congenital diseases of newborns that arise as a result of maternal drug exposure during 
pregnancy.
Congenital heart defects (CHDs) are the most common form of birth defects, with nearly 1% of newborns (about 
35,000–40,000) affected with CHDs every year1,2. All-trans retinoic acids (RAs) have been shown to play impor-
tant roles in organizing embryonic development through multiple signaling pathways3. However, 13-cis-RA, 
known as isotretinoin (INN) and used for the treatment of acne, is classified as a pregnancy category X drug 
by the FDA and is correlated with a high risk of birth defects. INN is therefore considered to be a teratogen and 
is prohibited for use by pregnant women4,5. It has been reported that administration of INN during pregnancy 
causes multiple types of malformations in infants, including cardiovascular, craniofacial, thymic, and neural 
developmental defects6–10. Unlike other RAs, INN exhibits low affinity for both RA receptors (RARs, for all-trans 
RA) and retinoid X receptors (RXRs, for 9-cis retinoic acid)4. Although INN has been widely used for derma-
tological therapy, its cellular and molecular mechanisms underlying developmental toxicity still remain poorly 
understood.
Human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) provide a valuable 
opportunity for the investigation of human diseases and drug screening. Compared to other animal models, 
human stem cells avoid species-specific effects that may arise during the use of non-human model organisms. 
Human stem cells can be differentiated into multiple types of cells, serving as organoids for specific disease mod-
els; therefore, this system obviates the limitations of using immortalized transformed cell lines (e.g., HepG2 and 
HEK293)11–13. For example, differentiation of cardiomyocytes derived from hiPSCs from clinical patients has 
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been used to study cardiac diseases and to evaluate drug-induced cardiotoxicity in hiPSC-derived cardiomyo-
cytes14–17. However, application of human stem cells to research in developmental toxicology (i.e., cells exposed to 
drugs during differentiation) has been rarely documented.
The objective of the present study was to elucidate the molecular mechanism(s) underlying INN-induced per-
turbation during early differentiation stages using human stem cells as an in-vitro model system. To accomplish 
this, we exposed both hESCs and hiPSCs to a sublethal concentration of INN during cardiomyocyte differentia-
tion. RNA sequencing (RNA-seq) and assay of transposase-accessible chromatin with high-throughput sequenc-
ing (ATAC-seq) were performed to determine the transcription factors (TFs) and gene-expression regulatory 
mechanism(s) linked to INN-induced perturbations at early stages of differentiation. We observed that INN 
specifically inhibited mesodermal differentiation. Integrative analyses of RNA-seq and ATAC-seq data revealed 
that INN-exposure caused dysregulation of genes involved in multiple signaling pathways important for meso-
dermal development.
Results
Developmental INN exposure inhibits mesoderm formation during cardiac differentiation. In 
the present study, we performed a monolayer-differentiation method to differentiate both hiPSCs and hESCs into 
cardiomyocytes as we have previously described18. Intermediate stages of cardiomyocyte differentiation include 
mesoderm formation (day2), cardiac mesoderm (days 4–5), and cardiomyocyte progenitors (day 6)18; finally, 
beating cardiomyocytes are observed after 7–10 days (Fig. 1A, and Supplementary videos 1 and 2).
Two steps of experiments were performed to determine the lowest-observed-adverse-effect level (LOAEL) of 
INN for this study. At the first step, dose-response experiments were performed to determine a sublethal con-
centration of INN for undifferentiated stem cells; at the second step, stem cells were exposed to a wide range of 
concentrations of INN identified from the first step during cardiomyocyte differentiation, so as to determine a 
LOAEL of INN, which does not impair the process of cardiac differentiation. Specifically, dose-response experi-
ments (0–50 μM) were performed to determine a sublethal concentration of INN for undifferentiated stem cells 
for 48 h. We chose 48 h as the differentiation medium was replaced every 48 h in the subsequent differentiation 
experiments. The doses-response curves of stem cells exposed to INN for 48 h are shown in Fig. 1B; both cell 
lines did not show mortality at concentrations below 5 μM. Moreover, pre-exposure to INN did not influence the 
self-renewal and proliferation of hESCs and hiPSCs, and the expression of pluripotency marker NANOG and 
surface marker TRA-1-60 were appropriately observed in the pre-exposed stem cells (Fig. 1C). The INN-exposed 
stem cells can still be differentiated to beating cardiomyocytes after removal of INN at the initiation of the differ-
entiation (Supplementary videos 3 and 4).
Subsequently, we exposed both C15-hiPSCs and H1-hESCs to a wide range of sublethal concentrations of 
INN (from 1 nM to 5 μM) during cardiomyocyte differentiation, all of which appeared to be non-toxic in these 
stem cells. We further observed that cellular morphology remained unchanged on day 2 after initiation of dif-
ferentiation (mesoderm stage) when the concentration exceeded 25 nM. On day 2, the control cells entered the 
mesoderm stage and highly expressed the Brachyury protein (Fig. 1D), a mesodermal marker encoded by gene T. 
In contrast, Brachyury was not observed in the INN-treated group, which exhibited a flatter colony surface. The 
INN-treated cells also exhibited a much smaller and denser morphology in the plates compared to the mesoderm 
cells in the control group (Fig. 1D,E). On day 6, the cells were differentiated into cardiomyocyte progenitors, and 
the cardiac markers NKX2-5 and TNNT2 were detected in the control group (Supplementary Figure 1). After day 
7, early beating cardiomyocytes were observed in the control group (Supplementary videos 1 and 2). However, 
cellular morphologic development remained nearly static in the INN-treated group during the differentiation 
after day 2, with only minimal detection of TNNT2 (Supplementary Figure 1).
In addition, we did not observe perturbation in cardiac differentiation if INN was added to the medium after 
mesoderm formation (data not shown), suggesting the detrimental effects of INN exposure are most pronounced 
during mesodermal differentiation. We also tested the effects of INN exposure on endoderm and ectoderm for-
mation, and observed that 25 nM INN had minor effects on ectoderm formation and moderate effects on endo-
derm formation, respectively (Supplementary Figures 2 and 3). Based on the flow-cytometry analysis, ectodermal 
cells were decreased 3% in C15-iPSCs and endodermal cells were decreased to about 27.5% in both C15-iPSCs 
and H1-hESCs compared to those in control (Supplementary Figure 3). Collectively, these results suggested that 
INN exposure exerted much more deleterious effects on mesodermal formation-especially during cardiac lineage 
differentiation.
Based on these results, we established 25 nM as the LOAEL of INN for disruption of mesoderm formation in 
this study. It is worth noting that this concentration is substantially lower than the average steady-state plasma 
concentration observed in patients (~670 nM)19. We next explored the transcription and chromatin accessibility 
patterns in stem cells upon exposure to 25 nM INN to gain new insight into the potential mechanisms driving 
INN-induced disruption during mesoderm formation derived from C15-iPSCs and H1-hESCs.
INN-exposure induces dysregulation of genes related to mesoderm differentiation during car-
diomyocyte differentiation. Identifying changes in transcription between control and drug-treatment 
may help provide insight into how INN-exposure disrupts mesoderm formation. Global gene expression pat-
terns were therefore profiled longitudinally at days 0, 2, and 6 by RNA-seq experiments in both control and 
INN-treated stem cells (Fig. 1A). Weighted gene co-expression network analysis (WGCNA), which calculates 
correlation values between individual gene expression profiles, was performed across these samples18,20. Overall, 
transcription patterns clearly cluster by time point and treatment condition. Furthermore, both C15 and H1 cells 
exhibit similar expression patterns in control and treatment groups (Fig. 2A), indicating that changes in tran-
scription induced by INN exposure are largely concordant between H1 and C15 cell lines.
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Further analysis reveals specific clusters of genes that respond differently between control and INN-treatment 
groups during differentiation. For example, several genes known to regulate mesoderm formation and cardiac dif-
ferentiation were highly expressed in control groups compared to the INN-treated groups on days 2 and 6, respec-
tively (Fig. 2A). These genes included EOMES, T, MIXL1, DKK1, NODAL and WNT3 on day 2; and TNNT2, 
MYH6, HAND2 and GATA4 on day 6 (Fig. 2A and Supplementary Table 1). The same pattern of sample segre-
gation was also observed by principal component analysis (PCA) (Fig. 2B). As one might expect, the enriched 
GO terms (biological process, BP) on day 2 included early mesoderm differentiation features, such as “pattern 
specification process”, “anterior/posterior pattern formation” and “embryonic morphogenesis” for both untreated 
Figure 1. INN-induced disruption of mesoderm formation during early cardiac differentiation. (A) 
Experimental design. Cardiomyocyte differentiation from both C15-hiPSCs and H1-hESC. Isotretinoin at a 
concentration of 25 nM was added to the medium during the differentiation process. Cells from two replicates 
of each line were collected on day 2 (mesoderm) and day 6 (cardiomyocyte progenitor) for RNA-seq and 
ATAC-seq. Undifferentiated stem cells on day 0 were collected and used as a reference. Two replicates of each 
cell line were used for RNA-seq and ATAC-seq. (B) Cell viability upon exposure to Isotretinoin for 48 h. (C) 
INN-exposure at 25 nM does not influence the pluripotency of the stem cells Immunostaining of stem cells 
(day 0) with TRA-1-60 (green) and NANOG (red), the nuclei were stained with DAPI (blue). No difference 
was observed between control and the INN-treated group. Both TRA-1-60 and NANOG were detected. (D–E) 
INN inhibits mesoderm formation during cardiac differentiation. Immunostaining of mesoderm cells with 
Brachyury (green) on day 2. No obvious Brachyury-expressed cells were found in the INN-treated cells by 
fluorescent microscopy (D) and flow cytometry analysis (E).
www.nature.com/scientificreports/
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H1 and C15 cell lines (Supplementary Table 2). On day 6, the GO term of “heart development” was appropriately 
enriched in control cells (i.e., cardiomyocyte progenitors) (Supplementary Table 2). However, these developmen-
tal stage-specific GO terms (e.g., embryonic morphogenesis) were not associated with the up-regulated genes in 
the treatment groups (Supplementary Table 3).
The differential genes (FDR <0.05) on day 2 exhibited similar changes in both H1 and C15 lines (Pearson cor-
relation coefficient 0.92). Genes commonly upregulated in H1 and C15 lines are related to “anterior/posterior pat-
tern specification” and “embryonic skeletal system morphogenesis”, whereas genes commonly downregulated are 
related to “primitive streak formation” and “signal transduction” (Fig. 2C and Supplementary Table 4), suggesting 
Figure 2. Analysis of genome-wide transcriptome of control and INN-treated groups during cardiac 
differentiation from day 0 to day 6. (A) Clustering analysis of transcriptomic profiles clustered by weighted 
gene co-expression network analysis (WGCNA). The heatmap represents the normalized counts by trimmed 
mean of M-values (TMM) normalization method. Representative dysregulated genes are shown, such as 
down-regulation of EOMES, T and NODAL in INN-treated cells. (B) PCA analysis of samples based upon their 
genome-wide transcriptomic profiles. (C) Left, MA-plot of the log-fold change against log-counts per million 
(log-CPM) of all genes. The differentially up- and down-expressed genes (FDR < 0.05) in INN-treated cells were 
labeled with red and blue, respectively. Right, Correlation plot of gene expression in INN-treated cells at day 2 
between C15 and H1. The representatively top up- and down-regulated genes are listed in the figure. Statistically 
enriched gene ontology (GO) (p < 0.05) of up-regulated genes between C15 and H1 are related to anterior/
posterior pattern specification and embryonic skeletal system morphogenesis, and down-regulated genes are 
related to primitive streak formation and signal transduction.
www.nature.com/scientificreports/
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genes involved in early developmental processes and signal transduction are aberrantly expressed in response to 
INN treatment at this early time point.
Transcription factor footprinting analysis reveals dynamic occupancy at specific regulatory ele-
ments after INN-exposure. To better understand the molecular determinants driving aberrant expression 
patterns upon INN treatment, we next profiled the regulatory chromatin landscape using ATAC-seq across each 
time-point and condition. Hierarchical clustering of genome-wide chromatin accessibility profiles revealed a 
strong correlation pattern in the global chromatin landscape between cell lines at each time-point (Fig. 3A), as 
similarly observed for transcription patterns (Fig. 2A). These results suggest that hESC and hiPSC cell lines show 
similar patterns of chromatin accessibility specific to INN exposure.
Beyond the general identification of open chromatin sites, ATAC-seq read ends can be exploited to identify 
TF motifs that are protected by protein-DNA interaction. This information can then be used to determine the 
likelihood of TF binding at a given regulatory element, which may provide insight into which factors are driving 
dynamic transcription patterns. We therefore identified transcription factor genome-wide footprints using the 
Protein Interaction Quantification (PIQ) footprinting algorithm21 against a curated motif database (http://jaspar.
genereg.net)22, filtering with a positive predictive value (PPV) cutoff of 0.7. Changes in chromatin accessibility 
were queried across putative TF binding sites (specifically their distance to the transcription start sites [TSS]) as 
a proxy for changes in regulatory element occupancy, and they were then compared with dynamic transcription 
patterns observed between control and INN-exposure conditions. We leveraged results from this combinatorial 
approach to identify potential regulatory mechanisms underlying INN-induced transcriptional disruption during 
mesoderm formation.
Comparison of TF footprint accessibility between treatment and control conditions (i.e. treatment vs. control) 
revealed that specific TFs showed enhanced overall chromatin accessibility at binding events after exposure to INN 
in both H1 and C15 lines, including HNF1 Homeobox B (HNF1B), SRY-Box 10 (SOX10) and Nuclear Factor I C 
(NFIC) (Fig. 3B). The differential accessibility scores of each TF footprint are shown in Supplementary Table 5. 
Further examination of genes that are proximal to HNF1B, SOX10, and NFIC binding sites revealed strong higher 
average FPKM values in the INN-exposure group, particularly for genes in which the TSS is immediately adjacent 
to the bound TF motif (Fig. 3C–E, further details provided in Supplementary Table 6). GO enrichment analysis 
revealed these proximal genes to be related to “anterior/posterior pattern specification”, “embryo organ morphogene-
sis”, and “regulation of by RNA polymerase II” in both H1 and C15 cell lines (Fig. 3C–E). Furthermore, inspection of 
aggregate chromatin accessibility in control and INN-treated cells further illustrates the higher signal intensity sur-
rounding the footprints identified for these TFs (Fig. 3C–E), demonstrating the strong correlation between dynamic 
gene expression and occupancy by these TFs. Importantly, analysis of protein expression levels also revealed a sig-
nificant spike in HNF1B protein specifically upon INN exposure. We also observed modest increases in protein 
levels of both SOX10 and NFIC (Fig. 3F), and changes in protein levels for these transcription factors are concordant 
with up-regulated mRNA expression levels upon INN exposure (Supplementary Figure 4). In combination with 
transcription and chromatin accessibility results, these results support a potential role for these factors in underlying 
aberrant expression patterns specific to INN exposure. Altogether, these results implicate HNF1B, SOX10, and NFIC 
as important transcriptional regulatory factors involved in the disruption of mesoderm formation.
Disruptions in signaling pathways due to INN exposure during mesoderm formation. The 
enrichment of GO terms related to early embryonic development and signaling pathways among INN-disrupted 
genes (Supplementary Tables 5 and 7) suggested to us that INN might primarily inhibit mesodermal develop-
ment by altering the expression of genes involved in signaling pathways that drive normal mesoderm formation. 
We therefore explored the expression of several sets of genes involved in multiple pathways to gain additional 
insights into the INN-induced disruption of signaling pathways during mesodermal differentiation from both 
cell lines. Relevant signaling pathways included Wnt/β-catenin, TGF-beta, NOTCH, and Hedgehog signaling, 
which are all known to regulate mesodermal differentiation23–29. Indeed, aberrant expression of genes related 
to these pathways, such as NOTCH1, NODAL and WNT5B, was observed in INN-treated samples compared to 
that in control (Fig. 4A–D). Furthermore, integration with the TF-footprinting results suggests that differential 
expression of genes involved in these signaling pathways is likely driven by aberrant binding of transcription fac-
tors, including HNF1B, SOX10, and NFIC (Fig. 4A–D). A schematic example of the TGF-beta signaling pathway 
in INN-treated C15 cells on day 2 is shown in Supplementary Figure 5, which shows up- and down-regulated 
genes involved in the pathway (red and green labels, respectively). Overall, increases in motif-accessibility and 
up-regulation of specific TFs suggests that INN-mediated dysregulation of gene expression is primarily driven 
via aberrant TF-binding, ultimately leading to disruption of signaling pathways that are necessary for normal 
mesoderm formation.
Discussion
In the present study, we demonstrate that INN exposure disrupts the mesoderm formation stage during cardiac 
differentiation of hESCs and hiPSCs. We found that a concentration of 25 nM INN is sufficient to disrupt meso-
derm formation, and deleterious effects are most dramatic on mesoderm compared to endoderm and ectoderm 
lineages. It is worth noting that this concentration is significantly lower than levels observed in the blood of actual 
patients19. We further uncover potential molecular mechanisms that may underlie INN-induced disruption of 
differentiation, shedding light on factors that may cause developmental abnormalities that give rise to congenital 
heart defects, the leading form of birth defects observed in newborns each year.
Teratogenic potency and placental transfer efficiency of INN varies among different species; human was consid-
ered to be particularly sensitive to INN compared to mammals (e.g., monkey, rabbit, rat and mouse)30. It has been 
reported that INN exhibits an extended half-life (16 hours) in human body compared to all-trans RA (1 hour)30,31. 
www.nature.com/scientificreports/
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Previous animal studies suggest that exogenous all-trans RAs and their metabolites (4-oxo-derivatives) showed 
higher teratogenicity than that of INN32,33. Moreover, INN exhibited lower activity in transactivation assays34, and 
its transcriptional regulation remains unclear due to low affinity for both RARs and RXRs4.
Conversely, based on genome-wide open-chromatin profiling of INN-treated cells during mesoderm differ-
entiation, we discovered that INN-exposure induced expression and enhanced genomic DNA-binding of several 
TFs, including HNF1B, SOX10 and NFIC. We also identified genes likely regulated by these TFs are involved in 
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Figure 3. Analyses of genome-wide chromatin landscape and enhanced TF-binding events in INN-treated 
groups during mesoderm differentiation. (A) Correlation of differential peaks in control and INN-treated 
groups of two cell lines during cardiomyocyte differentiation. (B) Median differential chromatin accessibility 
at TF motifs independently identified across H1 and C15 cell lines. HNF1B, SOX10, and NFIC show enhanced 
footprint accessibility in INN-treated cells on day2. (C–E) Left, Plotting of expression values (i.e., fragments 
per kilobase of transcript per million mapped reads [FPKMs]) of differential genes in close spatial proximity 
to the genomic binding sites of these TFs (specifically, within a moving window of 1500-bp distance to the 
transcription start site [TSS]). Middle, ATAC-seq signals (i.e. open chromatin peaks) around the center of TF-
binding sites across the whole genome in the treatment group is higher than that in control. Right, Top enriched 
gene ontology (GO) terms of the overlapping genes that were likely regulated by the TFs in both H1 and C15. 
The red dotted line denotes statistical significance (FDR <0.05) (F) Protein expression of HNF1B, SOX10, and 
NFIC in INN-treated and control cells on day2 using Western blot analysis. These TFs showed an up-regulation 
in INN-treated cells compared to that in control. Full-length blots of these cropped images are presented in the 
Supplementary Figure 7.
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important signaling pathways using computational biology methods. It is known that multiple signaling path-
ways are involved in the formation of the three germ layers (i.e., ectoderm, mesoderm, and endoderm), including 
Wnt/β-catenin, Notch, NODAL, BMP, Smad and FGF signaling27,28. It is also well-established that the mesoder-
mal cells yield formation of the heart tube35. These mechanisms are also seen in mesoderm differentiation derived 
from human stem cells in vitro23,26.
Endogenous all-trans RA is known to regulate early mesodermal differentiation, neural development and pat-
terning of the heart tube3,36–41. The enhanced protein expression of HNF1B, SOX10 and NFIC by INN exposure 
exhibited some similarity as seen in previous studies on RA-treatment, and these TFs play important roles in mul-
tiple differentiation process, including nephron, stomach development, beta cells and pancreatic precursor cells 
(HNFIB)42–45; osteoblast differentiation (NFIC)46; and neural crest differentiation (SOX10)47,48. The enriched GO 
terms of the INN-treated groups additionally reflect certain similarities with that of all-trans RA. For instance, 
up-regulated genes of the treatment groups are related to “neuron differentiation” (Supplementary Table 3), indi-
cating that INN exerts effects similar to all-trans RAs so as to induce expression of genes involved in neural dif-
ferentiation. However, no evidence of neuronal morphology was observed in INN-treated cells (Supplementary 
Figure 6). Thus, INN cannot be considered to be sufficient for neural development as endogenous RAs. In this 
study, we performed an in-vitro monolayer-differentiation method to evaluate impacts of INN on early meso-
dermal formation as well as ectoderm and endoderm. Embryonic development is more complex, thus validation 
for the interaction between INN, and these TFs and regulatory roles of these TFs, need to be addressed in future 
in-vivo studies.
Collectively, INN, as a 13-cis-RA, caused dysregulation of genes involved in signaling pathways underlying 
mesoderm differentiation via HNF1B, SOX10 and NFIC, leading to disruption in mesoderm formation. This 
study sheds new light on mechanistic studies in developmental toxicology by the use of human stem cells as an 
alternative system, and it also broadened our knowledge of mechanisms underlying congenital diseases of new-
borns due to maternal drug exposure during pregnancy at very low levels.
Materials and Methods
Chemicals. INN (Selleck Chemical LLC, TX) was prepared in dimethyl sulfoxide (DMSO), and then diluted 
to the final working concentration in medium for experiments.
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Figure 4. Signaling pathway analysis. (A–D) Heatmap represents expression of overlapping dysregulated 
of genes involved in multiple signaling pathways upon exposure to INN in both H1 and C15 cells on day2, 
including (A) TGF-beta signaling, (B) Wnt signaling, (C) Notch signaling, and (D) Hedgehog signaling. Right, 
the correlation between predicted target genes and the TFs based on footprinting analysis, i.e., correlation 
between transcription start site (TSS) and the bound TF motif. The cells labeled with orange means the genes 
were predicted to be likely regulated by the TFs.
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Cell culture and cell viability measurements. H1-hESC and C15-hiPSC lines were used in this study 
after obtaining them from the Stanford Cardiovascular Institute (SCVI) Biobank and the Stem Cell Core Facility 
of Genetics, Stanford University. The C15-hiPSC line was generated with lentivirus from skin fibroblasts from 
anonymous healthy persons. All pluripotent cell lines were grown in matrigel (Corning, CA)-coated 12-well 
plates in Essential 8™ Medium (Thermo Fisher Scientific, MA) at 37 °C in 5% CO2 in compressed air and 
high humidity. For cell viability tests, the H1 and C15 lines were placed in 24-well plates, and then exposed to 
graded concentrations (0–50 μM) of INN (in 0.1% DMSO as a vehicle control) from the second day for 48 h. The 
Celltiter-blue cell viability assay kit (Promega, WI) was used to measure cellular viability upon exposure to INN, 
and fluorescence intensity (excitation wavelength at 560 nm, emission at 590 nm) was recorded using a Tecan 
M1000 multimode plate reader (Tecan Systems, Inc., CA).
Stem cell differentiation and developmental exposure. Differentiation of ectoderm and endoderm 
was performed in 24-well plates using a STEMdiff™ Trilineage Differentiation Kit (STEMCELL Technologies) 
according to the manufacturer’s instructions. Cardiomyocyte differentiation was performed in 12-well plates 
using a monolayer differentiation method with a PSC Cardiomyocyte Differentiation kit (Thermo Fisher 
Scientific) as described in our previous publication18. The cells were exposed to INN (in 0.1% DMSO) dur-
ing the differentiation (Fig. 1A). We used 25 nM of INN as working concentration since we found it was a 
lowest-observed-adverse-effect level (LOAEL) of INN on cardiomyocyte differentiation (details see in Results). 
On days 0, 2, and 6 during cardiomyocyte differentiation period (before the medium was changed on that day), 
cells were collected using Accutase (Thermo Fisher Scientific). For each cell line and at each time-point, cells from 
two independent differentiation wells were used as two biologic replicates, and these collected cells were used for 
both RNA-seq and ATAC-seq experiments.
RNA-seq and data analysis. We used two replicates from each cell line for the RNA-seq analysis. Total RNA 
was extracted using the miRNeasy Mini Kit (Qiagen, CA), and RNA was then subjected to DNase I digestion and 
purified using a RNeasy Mini spin column (Qiagen) according to the manufacturer’s instructions. RNA integrity 
was checked with a NanoDrop, and only samples with a 260/280 ratio between 2.0–2.1 were subsequently used 
for ribosom depletion. Purified RNA (2.5 μg) was used for ribosomal depletion using with the Ribo-Zero™ Gold 
Kit (Human/Mouse/Rat) (Epicentre Biotechnologies) according to the manufacturer’s instructions. The integrity of 
ribosome-depleted RNA was assessed with the Agilent RNA 6000 Pico Assay kit on the Agilent 2100 Bioanalyzer 
(Agilent Technologies). RNA-seq libraries were constructed using a ScriptSeq™ v2 RNA-Seq Library Preparation 
kit (Epicentre Biotechnologies, WI) according to the manufacturer’s instructions. The concentration of the library 
was measured with a Qubit Fluorometer (Thermo Fisher Scientific) and the size was determined using an Agilent 
High Sensitivity DNA kit on an Agilent 2100 Bioanalyzer. All RNA-seq libraries were sequenced using HiSeq. 4000 
sequencers (Illumina) with 2 × 101 cycles. RNA-seq fastq data were aligned with Tophat49 (version 2.0.9) to the 
human hg19 reference genome. The human gene symbols and their raw counts were calculated using the HTSeq50. 
(version 0.6.1p1) package in Python with the hg19 Homo sapiens gtf file. Differential gene-expression analysis was 
performed using the edgeR package in R, and the normalization was performed using a trimmed mean of M-values 
(TMM) method across all samples51. In addition, Cufflinks (version 2.2.1) and GRCh37/hg19 Homo sapiens gtf 
file from UCSC Genome Browser were used to estimate transcripts abundance and generate their FPKM values. 
Hierarchical clustering analysis of transcriptome was performed using weighted gene co-expression network analy-
sis (WGCNA)20. The Gene Ontology (GO) enrichment analysis was performed using DAVID on-line tool (version 
6.8) (https://david.ncifcrf.gov/summary.jsp) and Gene Ontology Consortium (http://geneontology.org). The KEGG 
pathway52–54 analysis was performed using GAGE and Pathview55,56 packages in R.
ATACseq and data analysis. We used two replicates from each cell line for the ATAC-seq analysis. The 
ATAC-seq protocol developed by Buenrostro et al.57 was used for profiling of chromatin landscape. 50,000 cells of 
each sample were collected and pelleted by centrifugation for 15 min at 500 g and 4 °C. Cell pellets were washed 
once with ice-cold 1x PBS and then pelleted again by centrifugation at the previous settings. Cell pellets were 
re-suspended in 25 μl of ice-cold lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2, and 0.1% Igepal 
CA-630, pH 7.4), and nuclei were pelleted by centrifugation for 30 min at 500 g and 4 °C. Supernatants were 
discarded and nuclei were re-suspended in 50 μl reaction buffer (2 μl of Tn5 transposase and 12.5 μl of TD buffer 
from a Nextera DNA Library Prep Kit from Illumina, and 22.5 μl nuclease-free H2O). The reaction was incubated 
at 37 °C for 30 min, and subsequently the reaction mixture was purified using MinElute PCR Purification Kit 
(Qiagen). The purified transposed DNA was amplified with NEBNext High-Fidelity 2 X PCR Master Mix (New 
England Biolabs) and custom-designed primers with barcodes57. Gel electrophoresis was used to remove primer 
dimers from the PCR products with 2% E-Gel EX Agarose Gels (Thermo Fisher Scientific), and then the PCR 
products were purified using QIAquick PCR Purification Kit (Qiagen). DNA concentration was measured with a 
Qubit Fluorometer (Thermo Fisher Scientific) and library sizes were determined using an Agilent High Sensitivity 
DNA kit on an Agilent 2100 Bioanalyzer. The ATAC-seq libraries were sequenced with a HiSeq. 2000 sequencer 
(Illumina) with 2 × 101 cycles, and the sequencing quality control was performed by the Stanford Center for 
Genomics and Personalized Medicine.
The raw data were then trimmed to remove the adapter sequences (CTGTCTCTTATACACATCT) with 
command-line tool cutadapt (1.8.1). The trimmed files were mapped to the human genome (hg19) using 
Bowtie2 (2.1.0) with default parameters. Read pairs, which aligned concordantly to the genome and had 
a mapping quality greater than 10, were kept for subsequent analysis. Mapping rate and mapped reads of the 
ATAC-seq data are shown in Supplementary Table 8. Read pairs mapped to mitochondrial DNA were discarded. 
Redundancy read pairs from PCR amplification were also removed afterward using Picard tools (version 1.79). 
Open accessible-regions for each library were defined by the peaks called by MACS2 (2.1.0) with the parameters 
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“-g hs–nomodel–shift 0 –q 0.01”. Peaks located at blacklist genomics regions were removed using bedtools 
(2.25.0). These tracks show artifactual regions that tend to show artificially high signal and were identified by the 
ENCODE and modENCODE consortia58. The annotations of the peaks were achieved using ChIPpeakAnno, org.
Hs.eg.db, and EnsDb.Hsapiens.v75 packages in R.
Computational footprinting of TF-binding analysis. TF-footpinrting analysis was divided into two 
steps. The first step identifies sites throughout the genome where a motif is likely to be bound (i.e., footprint). The 
second step assigns a score to indicate differential binding or chromatin accessibility over footprints identified in 
the step 1 (differential footprint). We used merged bam files (mapped to gene coordinates) from each replicate to 
achieve enough sequencing depth for the footprinting analysis. Specifically, putative TF footprints were identified 
using the Protein Interaction Quantification (PIQ) footprinting algorithm21 against the JASPAR core vertebrate 
database (http://jaspar.genereg.net)22 of TF motifs as described in our previous publication18. Motifs matching the 
database of known TF target sequences were performed against the hg19 reference genome using the PIQ package 
pwmmatch.exact.r script. Afterwards, filtered ATAC-seq alignment reads were converted into binary RData files, 
and TF footprint scores were determined for each motif match using the PIQ package pertf.bg.r and common.r 
scripts with default settings. Putative TF footprints were filtered at a positive predictive value (PPV) cutoff of 0.7 
(i.e., 70% of sites are bound after filtering) and, in each experiment the total number of binding events were then 
compared across conditions. In order to investigate relationships between TF-occupancy and gene regulation, the 
closest coding genes were assigned for each TF footprint/occupancy based on their transcription start sites (TSS) 
using bedtools closest command line of bedtools software (version 2.26.0). The differential footprint analysis was 
performed with Wellington-bootstrap algorithms59.
Immunostaining. Immunostaining of three germ layers was performed using a Human Three Germ Layer 
3-Color Immunocytochemistry Kit (R&D Systems). For immunostaining of cells during cardiomyocyte differ-
entiation, the pluripotent cells were grown and differentiated in a glass-bottomed 12-well plate (MatTek, MA), 
and then cells were fixed and permeated in the plate using a Human Cardiomyocyte Immunocytochemistry Kit 
(Thermo Fisher Scientific). The primary antibodies included mouse anti-TRA-1-60 (ESI BIO, ST11016), rabbit 
anti-Nanog (Stemgent, 09-0020), goat anti-Brachyury (Fisher Sciences, AF2085), rabbit anti-Pax6 (BioLegend, 
901301), rabbit anti-Nkx2-5 and mouse anti-Tnnt2 (Thermo Fisher Scientific, A25973). Secondary antibodies 
included goat anti-mouse IgG (Alexa Fluor 488 conjugated, Thermo Fisher Scientific, A10680), donkey anti-goat 
IgG (DyLight 488 conjugated, Thermo Fisher Scientific, SA5-10086), goat anti-rabbit IgG (H + L) Alexa Fluor 
488 (Thermo Fisher Scientific, A-11034), and donkey anti-rabbit IgG (Alexa Fluor 594 conjugated, Thermo Fisher 
Scientific, A21207). The images were taken using Leica DMi8 Microsystems and Zeiss LSM710 inverted confocal 
microscope, and then the images were processed using the Fiji software.
Flow cytometry and analysis. Differentiating cells (50,000 cells) on day 2 were collected for flow cytom-
etry. The cells were washed with DPBS buffer (Thermo Fisher Scientific), and then were fixed and permeabilized 
using Cytofix/Cytoperm (BD Biosciences). Afterwards, the cells were labeled with mouse anti-Brachyury (Abcam, 
ab140661) and goat anti-mouse IgG (Abcam, Alexa Fluor 488 conjugated, ab150117). In addition, mouse Otx2 
Alexa Fluor® 488-conjugated antibody (R&D Systems, IC1979G-025) and mouse SOX17 PE-conjugated anti-
body (R&D Systems, IC19241P) were used for and ectoderm and endoderm, respectively. Ice-cold DPBS (with 
1% FBS) was used as the flow cytometry buffer for re-suspending cells. Flow cytometry was performed using a 
FACSAria II cytometer (BD Biosciences). The data were analyzed using FlowJo software (version 10.1).
Real-time QPCR. cDNA was synthesized from 1 μg of total RNA using an SuperScript VILO cDNA Synthesis 
Kit (Thermo Fisher Scientific) following the manufacturer’s protocol. 18S rRNA was used as a normaliz-
ing gene. PCR amplification was performed with a QuantStudio™ 6 Flex Real-Time PCR System (Thermo 
Fisher Scientific) in 20-μl reactions using 1 μl of cDNA (10 ng of total input RNA), 200 nM of each forward 
and reverse primer and 1X PowerUp SYBR™ Green Master Mix (Applied Biosystems). The real-time PCR 
program consisted of 1 cycle of 95 °C for 5 min; and 40 cycles of 95 °C for 15 s, 58 °C 30 s and 72 °C for 30 s. 
Relative gene expression data were calculated using the ΔΔCt method60. The primer sequences for NFIC are61: 
forward, 5′-GGACAGGGATGGGCTCTG-3′; reverse, 5′-CGTTCTTCTGAGGCCAGTGC-3′. The primer 
sequences for SOX10 are62: forward, 5′-GACCAGTACCCGCACCTG-3′; reverse, 5′-CGCTTGTCACTTTCG 
TTCAG-3′. 18S rRNA was used as a normalizing gene, and the primer seuqneces are63: forward, 
5′-GCAATTATTCCCATGAACG-3′; reverse, 5′-GGGACTTAATCAACGCAAGC-3′.
Western blot. The cells were harvested in RIPA lysis buffer (EMD Millipore, CA) contain one tablet of 
Pierce™ protease and phosphatase inhibitor (Thermo Fisher Scientific), and the proteins were purified using 
a Branson Digital Sonifier homogenizer (Branson Ultrasonics). 15 μg of protein from each sample was sepa-
rated on NuPAGE 4–12% Bis-Tris protein gels (Thermo Fisher Scientific) and transferred to nitrocellulose 
membranes (Thermo Fisher Scientific). The protein-bound membranes were blocked with 5% of blotting-grade 
blocker (Bio-Rad) in PBST for one hour at room temperature and incubated with a primary antibody in 5% of 
blotting-grade blocker in PBST overnight at 4 °C. After washing with PBST buffer, the membranes were incubated 
with horseradish peroxidase (HRP)-conjugated-secondary antibody for 1 h at room temperature. The membranes 
were developed with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) and 
exposed on a ChemiDoc Touch imaging system (Bio-Rad) for imaging. The primary antibody used in this study 
included rabbit anti-HNF1B (Abcam, ab128912), rabbit anti-SOX10 (Bethyl Laboratories, A305-521A-T), rabbit 
anti-NFIC (Bethyl Laboratories, A303-123A-T). The secondary antibody was HRP-conjugated-goat anti-rabbit 
IgG (GE Healthcare, RPN4301). Mouse anti-beta actin (horseradish Peroxidase [HRP] conjugated) (Invitrogen, 
MA515739HRP) was used as the reference.
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Data availability. Both RNA-seq and ATAC-seq data generated for this work have been deposited in 
NCBI’s Gene Expression Omnibus (GEO), and they are accessible through GEO SuperSeries accession number 
GSE85881: GSE85880 for the RNA-seq, and GSE85879 for the ATAC-seq.
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